42011-36-9

Upstream product

• 5987-78-0 p-nitrophenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyde 
• 2492-87-7 4-nitrophenyl-β-D-glucoside 
• 100-02-7 4-nitro-phenol 
• 83-87-4 D-glucose pentaacetate 
• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 604-69-3 β-D-glucose pentaacetate 
• 5197-95-5 benzyltriethylammonium bromide 
• 3947-62-4 2,3,4,5-tetra-O-acetyl-D-glucopyranose 
• 6919-96-6 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 74808-10-9 O-(2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl)trichloroacetimidate 
• 123-30-8 4-amino-phenol 
• 3068-32-4 1-bromo-1-deoxy-2,3,4,6-tetra-O-acetyl-a-D-galactopyranoside 
• 2872-66-4 4-nitrophenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 
• 3150-24-1 4-nitrophenyl-β-D-galactopyranoside 

Downstream Products

• 20818-25-1 4-aminophenyl β-D-glucopyranoside 
• 122078-56-2 2,5-dimethylphenolindophenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 134136-38-2 7-N-<4-O-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)phenyl>-9a-methoxymitosane 
• 91255-92-4 Acetic acid (2S,3R,4S,5R,6R)-4,5-diacetoxy-6-acetoxymethyl-2-(4-acryloylamino-phenoxy)-tetrahydro-pyran-3-yl ester 
• 122078-55-1 phenolindophenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 122078-57-3 1-naphtholindophenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 129253-65-2 N-(2-naphthoquinonyl)-4-aminophenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 362660-94-4 4-Retinamidophenyl-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 249512-62-7 Acetic acid (2R,3R,4S,5R,6S)-3,5-diacetoxy-2-acetoxymethyl-6-(4-formylamino-phenoxy)-tetrahydro-pyran-4-yl ester 
• 946602-87-5 C₃₂H₄₅NO₁₃ 
• 946602-85-3 C₄₈H₆₈N₂O₁₈ 
• 946602-86-4 C₃₄H₅₁N₃O₁₂ 

Relevant academic research and scientific papers

Hydrogel behavior of a sugar-based gelator by introduction of an unsaturated moiety as a hydrophobic group

The new sugar-based gelators 1 and 2 were synthesized, and their gelation abilities were evaluated in organic solvents and in water. Compound 1 gelates both water and organic solvents whereas 2 gelates only organic solvents. Superstructural difference between hydrogel 1 and organogel 2 was investigated by CD, TEM, AFM, 1H NMR and XRD. Hydrogel 1 displays a well-developed helical ribbon structure with 20-150 nm diameter and a length of several hundred m whereas organogel 2 shows a twisted fiber structure of diameter 20 nm. CD measurements of hydrogel 1 and organogel 2 indicate that hydrogel 1 maintains a well-ordered chiral structure whereas organogel 2 maintains a relatively disordered chiral structure. The 1H NMR and XRD results suggest that the hydrophobic interaction in hydrogel 1 are relatively weak, with a relatively small region interdigitated between lipophilic alkyl groups. In addition, upon irradiation at 254 nm wavelength, hydrogel 1 reveals a red coloration at 540 nm. These results indicate that the self-assembled hydrogel 1 was polymerized by UV-irradiation. The intensity of the CD spectrum of the polymerized hydrogel markedly decreased. This result indicates that upon polymerization the highly ordered chiral structure of hydrogel 1 changes to a disordered molecular packing structure. The Royal Society of Chemistry 2006.

Nitrogen-containing aromatic ring derivative containing galactose and application thereof

The invention belongs to the technical field of medicines, and relates to a nitrogen-containing aromatic ring derivative containing galactose, application thereof and a pharmaceutical composition containing the compound. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in prevention or treatment of tumors, inflammatory diseases, autoimmune diseases and other diseases, especially tumors.

Glucose-containing nitrogen-containing aromatic ring derivative and application thereof

The invention belongs to the technical field of medicines, and relates to a glucose-containing nitrogen-containing aromatic ring derivative and application thereof, and a pharmaceutical composition containing the compound. The invention also relates to a

Functionalised bicyclic tetramates derived from cysteine as antibacterial agents

Routes to bicyclic tetramates derived from cysteine permitting ready incorporation of functionality at two different points around the periphery of a heterocyclic skeleton are reported. This has enabled the identification of systems active against Gram-positive bacteria, some of which show gyrase and RNA polymerase inhibitory activity. In particular, tetramates substituted with glycosyl side chains, chosen to impart polarity and aqueous solubility, show high antibacterial activity coupled with modest gyrase/polymerase activity in two cases. An analysis of physicochemical properties indicates that the antibacterially active tetramates generally occupy physicochemical space with MW of 300-600, clog D7.4 of -2.5 to 4 and rel. PSA of 11-22%. This work demonstrates that biologically active 3D libraries are readily available by manipulation of a tetramate skeleton.

Development of Pseudomonas aeruginosa Lectin LecA Inhibitor by using Bivalent Galactosides Supported on Polyproline Peptide Scaffolds

LecA is a galactose-binding tetrameric lectin from Pseudomonas aeruginosa involved in infection and biofilm formation. The emergent antibiotic resistance of P. aeruginosa has made LecA a promising pharmaceutical target to treat such infections. To develop LecA inhibitors, we exploit the unique helical structure of polyproline peptides to create a scaffold that controls the galactoside positions to fit their binding sites on LecA. With a modular scaffold design, both the galactoside ligands and the inter-ligand distance can be altered conveniently. We prepared scaffolds with spacings of 9, 18, 27, and 36 ? for ligand conjugation and found that glycopeptides with galactosides ligands three helical turns (27 ?) apart best fit LecA. In addition, we tested different galactose derivatives on the selected scaffold (27 ?) to improve the binding avidity to LecA. The results validate a new multivalent scaffold design and provide useful information for LecA inhibitor development.

Synthetic multivalent ligands for cholera & cholera-like toxins: Protected cyclic neoglycopeptides

Synthesis of a set of novel glycopeptide analogues as potential cholera/cholera-like toxin inhibitors in their protected form is described. They include di-, tri-, tetra- and pentavalent scaffolds. The synthetic steps were achieved using a combination of solvent-free mechanochemical as well as the conventional solution-phase reactions. During the conventional DIC-HOBt-mediated peptide coupling followed for the preparation of certain glycopeptide analogues an interesting in situ Fmoc deprotection was observed which has been demonstrated to hold potential for synthesiszing glycopeptides/neoglycopeptides with extended polyamide chains.

Development and optimization of a competitive binding assay for the galactophilic low affinity lectin LecA from: Pseudomonas aeruginosa

Infections with the Gram-negative bacterium Pseudomonas aeruginosa result in a high mortality among immunocompromised patients and those with cystic fibrosis. The pathogen can switch from planktonic life to biofilms, and thereby shields itself against antibiotic treatment and host immune defense to establish chronic infections. The bacterial protein LecA, a C-type lectin, is a virulence factor and an integral component for biofilm formation. Inhibition of LecA with its carbohydrate ligands results in reduced biofilm mass, a potential Achilles heel for treatment. Here, we report the development and optimization of a fluorescence polarization-based competitive binding assay with LecA for application in screening of potential inhibitors. As a consequence of the low affinity of d-galactose for LecA, the fluorescent ligand was optimized to reduce protein consumption in the assay. The assay was validated using a set of known inhibitors of LecA and IC50 values in good agreement with the known Kd values were obtained. Finally, we employed the optimized assay to screen sets of synthetic thio-galactosides and natural blood group antigens and report their structure-activity relationship. In addition, we evaluated a multivalent fluorescent assay probe for LecA and report its applicability in an inhibition assay.

Preparation method of galactose-containing fatty acid derivative and application of preparation method in field of medicine

The invention relates to a novel p-fatty alkylamide phenyl-beta-D-galactoside compound, a preparation method and application, belonging to the technical field of medicine. A structure general formula of the compound is shown in the description, wherein R is selected from (CH2)6CH3, (CH2)10CH3, (CH2)12CH3, (CH2)14CH3, and (CH2)7CH=CH (CH2)7CH3. The compound has stronger inhibitory activity to tumor cells, and can be used for tumor therapies.

Glycosylated lanthanide cyclen complexes as luminescent probes for monitoring glycosidase enzyme activity

The development of synthetic chemical probes for the detection of enzymes is extremely important for biological, medicinal, and industrial applications. Here we report the synthesis of an array of novel glycosylated Tb(iii) complexes, their photophysical properties in solution, and their ability to function as luminescent probes for observing glycosidase enzyme activity in real time. Our initial studies into the application of these complexes for the detection of the Concanavalin A (ConA) lectin is also reported, highlighting the broad scope of these novel chemical probes.

Glucose fatty acid-containing derivative preparation method and application of derivative in medical field

The invention relates to a novel p-fatty alkyl amidophenyl-beta-D-glucoside compound and a preparation method and an application thereof, which belong to the technical field of medicine. According to the invention, a structural general formula is shown as